双免疫检查点特异性抗体在晚期非小细胞肺癌治疗中的研究进展  

Advances in dual immune checkpoint-specific antibodies in the treatment of advanced NSCLC

作　　者：郭佳禄 杨宇[1] Guo Jialu;Yang Yu(Internal Medicine-Oncology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科,哈尔滨150086

出　　处：《中国肿瘤临床与康复》2024年第7期407-415,共9页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：肺癌位居我国恶性肿瘤发病率及死亡率首位,非小细胞肺癌(NSCLC)约占肺癌总发病人数的80%,疾病负担较重。近年来,针对NSCLC的化疗、分子靶向治疗和免疫治疗取得了突破性的进展,但仍然难以完全满足临床需求。基于免疫疗法的双免疫检查点抑制剂及同时靶向2个靶点的双特异性抗体是目前最新研发方向,已被大量基础研究实验论证,也逐渐被临床指南所推荐。文章概括了免疫治疗的机制和临床应用的现状,并总结双免疫检查点抑制剂在NSCLC临床试验中的有效性和不良反应,展望双特异性抗体未来应用的可能方向。Lung cancer ranks first in both incidence and mortality among malignant tumors in China,with non-small cell lung cancer(NSCLC)accounting for approximately 80%of all lung cancer cases,posing a significant disease burden.In recent years,significant breakthroughs have been made in the treatment of NSCLC through chemotherapy,molecular targeted therapy,and immunotherapy.However,these advances still fail to fully meet clinical demands.Dual immune checkpoint inhibitors and bispecific antibodies,which target two immune checkpoints or antigens simultaneously,represent the latest research direction in immunotherapy.These approaches have been extensively validated in preclinical studies and are increasingly recommended in clinical guidelines.This article summarizes the mechanisms and current clinical applications of immunotherapy,reviews the efficacy and adverse effects of dual immune checkpoint inhibitors in clinical trials for NSCLC,and explores the potential future directions for the application of bispecific antibodies.

关 键 词：癌 非小细胞肺 双免疫检查点抑制剂 免疫治疗 双特异性抗体 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]